
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx is facing a variety of risks, including clinical and regulatory, financial, commercial, legal and intellectual property, and market share risks. However, the company expects an improvement in revenue growth through 2026 and a return to growth in both the US and international markets. The recently implemented leadership transition and focus on sales force productivity, account quality, and cost control may help stabilize the company, and upcoming earnings will provide insight into whether U.S. treatment center utilization and patient conversion can reaccelerate.
Bears say
Pulmonx is facing several challenges, including weaker U.S. performance and slower procedure growth, as the company struggles to maintain operational discipline and reaccelerate commercial efforts. The company's financial results for the fourth quarter and full year of 2025 showed modest annual growth but a decline in quarterly revenue, indicating a transitional period for the company. In order to regain investor confidence, Pulmonx will need to demonstrate a clean fourth quarter print and show improvement in procedural velocity and cost control while remaining the leader in bronchoscopic lung volume reduction.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares